Role of Microbiome in BCG Responsiveness Prediction

Summary

Our primary aim is to investigate the use of microbial profile from the bladder and the feces of NMIBC patients as a predicting tool for therapy response prior to BCG administration. Our second aim is to collect additional samples (blood, instrumented urine, bladder tissue, feces) to establish a local biobank for future microbiome projects.

Eligibility

Inclusion Criteria

* Signed informed consent
* Ability to understand and follow study procedures and understand informed consent
* age 18 - 90 years

Exclusion Criteria

* Antibiotic treatment within the last month
* Immuno-/chemotherapy within the past 6 months
* Immunosuppressive therapy
* Major medical, neoplastic (with the exception of skin cancer), surgical or psychiatric condition requiring ongoing management. Minor, well-controlled conditions, such as medically controlled arterial hypertension or occupational asthma, may be present.
* Additional major diagnosis known to affect the gut or bladder microbiota (e. g. liver cirrhosis, systemic sclerosis, inflammatory bowel disease, inflammatory bowel syndrome, celiac disease, neuropathic bladder)
* Major past intestinal surgery, especially in small intestine or colon. Cholecystectomy, appendectomy, past perianal surgery or past hernia repair may be present.
* Major gastrointestinal symptoms (diarrhoea, constipation, abdominal pain, vomiting, unexplained weight loss, rectal bleeding or blood in the stool)
* Bladder augmentation surgery.
* Indwelling urinary catheter

Conditions3

Browse More Trials